ANRO vs. PCRX, BLTE, KNSA, SYRE, MNKD, ANIP, AKRO, DAWN, MIRM, and ABCL
Should you be buying Alto Neuroscience stock or one of its competitors? The main competitors of Alto Neuroscience include Pacira BioSciences (PCRX), Belite Bio (BLTE), Kiniksa Pharmaceuticals (KNSA), Spyre Therapeutics (SYRE), MannKind (MNKD), ANI Pharmaceuticals (ANIP), Akero Therapeutics (AKRO), Day One Biopharmaceuticals (DAWN), Mirum Pharmaceuticals (MIRM), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical preparations" industry.
Alto Neuroscience (NYSE:ANRO) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, community ranking, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.
Pacira BioSciences has higher revenue and earnings than Alto Neuroscience.
99.7% of Pacira BioSciences shares are held by institutional investors. 6.4% of Pacira BioSciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, Pacira BioSciences had 7 more articles in the media than Alto Neuroscience. MarketBeat recorded 8 mentions for Pacira BioSciences and 1 mentions for Alto Neuroscience. Alto Neuroscience's average media sentiment score of 0.00 beat Pacira BioSciences' score of -0.10 indicating that Alto Neuroscience is being referred to more favorably in the media.
Pacira BioSciences has a net margin of 10.34% compared to Alto Neuroscience's net margin of 0.00%. Pacira BioSciences' return on equity of 12.98% beat Alto Neuroscience's return on equity.
Pacira BioSciences received 803 more outperform votes than Alto Neuroscience when rated by MarketBeat users. However, 100.00% of users gave Alto Neuroscience an outperform vote while only 71.81% of users gave Pacira BioSciences an outperform vote.
Alto Neuroscience presently has a consensus price target of $32.33, indicating a potential upside of 170.35%. Pacira BioSciences has a consensus price target of $47.40, indicating a potential upside of 56.28%. Given Alto Neuroscience's higher probable upside, analysts plainly believe Alto Neuroscience is more favorable than Pacira BioSciences.
Summary
Pacira BioSciences beats Alto Neuroscience on 10 of the 14 factors compared between the two stocks.
Get Alto Neuroscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANRO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alto Neuroscience Competitors List
Related Companies and Tools
